Eton Pharmaceuticals Announces Acquisition of FDA-Approved Rare Disease Product, Betaine Anhydrous for Oral Solution

Rhea-AI Summary

Eton Pharmaceuticals (Nasdaq: ETON) announced the acquisition of betaine anhydrous for oral solution, enhancing its portfolio focused on rare diseases. This FDA-approved product targets fewer than 2,000 patients in the U.S. with a market estimated at $10 million annually. CEO Sean Brynjelsen highlighted that the acquisition is expected to be accretive to 2023 earnings and aligns with their strategy to commercialize treatments for underserved populations. Eton plans to integrate the product later this year.

Positive

• Acquisition expected to be accretive to 2023 earnings.
• Betaine targets a niche market with an estimated annual value of $10 million.
• Strengthens existing commercial infrastructure with shared prescriber base.
• Advances Eton's mission in rare disease treatment.

Negative

• None.

-- Expected to be accretive to 2023 earnings --

DEER PARK, Ill., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the acquisition of betaine anhydrous for oral solution.

"We are excited to add another FDA-approved rare disease product to our growing metabolic genetics portfolio. Betaine shares the same prescriber base as our carglumic acid tablets, so it is an attractive opportunity to leverage our existing commercial infrastructure. We plan to integrate the product later this year and expect the transaction to be accretive to 2023 earnings,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals. “This acquisition allows us to further advance our mission of commercializing products for small, underserved orphan populations, and we will continue to seek out attractive late-stage rare disease products to expand our portfolio.”

Betaine anhydrous for oral solution targets a population of fewer than 2,000 patients in the United States, with an estimated market of $10 million annually.

About Eton Pharmaceuticals
Eton Pharmaceuticals, Inc. is an innovative pharmaceutical company focused on developing, acquiring, and commercializing treatments for rare diseases. The Company currently commercializes ALKINDI SPRINKLE® and Carglumic Acid tablets and has four additional rare disease products under development, including dehydrated alcohol injection and the ZENEO® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com.

Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com

Source: Eton Pharmaceuticals

FAQ

What is the significance of Eton Pharmaceuticals acquiring betaine anhydrous for oral solution?

The acquisition is expected to enhance Eton's portfolio in rare diseases and contribute positively to 2023 earnings.

How many patients does betaine anhydrous for oral solution target?

Betaine anhydrous targets a population of fewer than 2,000 patients in the United States.

What is the estimated market value for betaine anhydrous for oral solution?

The estimated market value for betaine anhydrous is approximately $10 million annually.

When does Eton plan to integrate betaine anhydrous into their offerings?

Eton plans to integrate betaine anhydrous later this year.

How does this acquisition align with Eton Pharmaceuticals' business strategy?

The acquisition supports Eton's strategy to commercialize products for small, underserved orphan populations and expand its metabolic genetics portfolio.